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INTRODUCTION
Postoperative  nausea  and  vomiting  are  multifactorial  in 
etiology.  It  remains  a  common  problem  after  general 
anesthesia and contributes to patient dissatisfaction.  In a study 
conducted by Eberhart et  al,  nearly 50% of patients mentioned 
PONV as the postoperative side effect of greatest concern1. 
But,  much  importance  has  been  given  to  post-op  pain 
relief  than  to  prevention  of  post-operative  nausea  and 
vomiting.  When  severe,  post-op  nausea  and vomiting  can  lead 
to  wound  dehiscence,  bleeding,  dehydration,  electrolyte 
imbalance,  delayed  discharge  from  PACU,  and  increased 
treatment cost to patients.   
AIM OF THE STUDY
The  aim  of  this  study  is  to  compare  the  effect  of 
ondansetron  and  granisetron  in  the  prevention  of  post-operative 
nansea  and  vomiting  in  patients  undergoing  tonsillectomy  and 
middle  ear  surgery  and  to  evaluate  the  safety  of  the  drugs  by 
studying the incidence of side-effects.
PHYSIOLOGY OF NAUSEA AND VOMITING
The syndrome of nausea,  retching and vomiting is known 
as  sickness  and  each  of  it  can  be  distinguished  as  a  separate 
entity.
Nausea :  It is a subjective sensation of the desire to vomit,  but 
without any attempt at expulsive movements.
It is frequently accompanied autonomic phenomenon, resulting 
in  objective  signs  such  as  secretion  of  saliva,  sweating, 
increase  in  pulse  rate,  variations  in  rate,  depth  and  regularity 
of respiration, pallor, and pupillary dilation.
Retching and vomiting:  Both are active exclusive mechanisms, 
and  are  differentiated  by  the  end  result  of  the  process. 
Vomiting  results  in  forceful  expulsion  of  gastric  contents 
through the mouth, whereas retching causes no expulsion.
Mediators of vomiting reflex :
Vomiting  is  initiated  by  an  afferent  pathway  which 
carries signals from both the viscera and certain areas of brain. 
These  impulses  are  transmitted  to  specialized  centres  in  the 
brain.  Appropriate  motor  reactions  then  occur  to  cause  the 
vomiting act.
Afferent
1) Visceral receptors
2) CTZ
3) Vestibular system
4) Cortex
5) Glossopharyngeal stimulation 
Central integrative mechanism 
1) Vomiting centre
2)  Nucleus tractus solitarius
Efferents 
1) Cranial nerves to upper GIT
2) Spinal nerves to diaphragm and abdominal muscles
Afferent pathway
1. Visceral receptors :
Chemoreceptors  They  are  located  in  upper  G1,  and 
respond  to  GI  irritation  which  release  5–HT  from  entero 
chromaffin cells. 
Mechanoreceptors :   
Found in the muscle layer of GI. These receptors respond 
to  distention,  contraction  of  GIT  and  physical  damage  by 
surgical stimuli etc.,
Both  these  receptors  transmit  signals  through  the  vagus 
and sympathetic afferents via the spinal cords.
2) CTZ :
The  chemoreceptor  trigger  zone  (CTZ)  is  located  in  the 
area  postrema  in  the  floor  of  the  fourth  ventricle.  It  responds 
to  blood  borne  drugs,  like  opioids,  digoxin,  mediators.like 
dopamine, 5-HT, histamine harmones, toxins etc.,  because it is 
unprotected by the blood – brain barrier.
3) Vestibular system :
When body is rotated or equilibrium is disturbed or when 
ototoxic drugs act,  the  vestibular  apparatus sends signal  to the 
vomiting centre via the cerebellum.
4) Cortex : 
Various  psychic  stimuli  like  bad  odour,  ghastly  sight, 
severe  pain,  fear,  recall  of  an  obnoxious  event  cause  nausea 
and vomiting through higher centres.
5)Glossopharyngeal stimulation :
Stimulating  the  back  of  the  throat  stimulates  vomiting 
centre via the nucleus tractus solitarius.
Central intergrative mechanism :
Vomiting  occurs  due  to  stimulation  of  vomiting  centre 
situated in the medulla by the afferent  impulses reaching it  via 
the nucleus tractus solitarius.  Head injury raised ICT, psychic 
stimuli  and  vestibular  impulses  directly  stimulate  vomiting 
centre.
Efferent Pathway
 The  motor  impulses  that  cause  actual  vomiting  are 
transmitted  from vomiting  centre  through the  5 t h ,  7 t h ,  9 t h ,  10 t h , 
and 12 t h ,  cranial  nerves to the upper GI and through the spinal 
nerves to the diaphragm and abdominal muscles
1) Antiperistalsis,  the preclude to vomiting :
Antiperistalsis  may  begin  as  far  down  in  the  GI  as  the 
ileum,  many  minutes  before  vomiting  appears.  The  waves 
travel  up  the  intestine  at  a  rate  of  2  –  3  cm/sec,  pushing  the 
intestinal  contents  to  the  stomach  and  duodenum within  3  –  5 
minutes.  Just  prior  to  vomiting,  strong  contractions  occur  in 
the  stomach  and  duodenum  along  with  partial  relaxation  of 
LES,  allowing  the  vomitus  to  begin  moving  into  the 
oesophagus.
2) The vomiting act :
Once the vomiting centre has been sufficiently stimulated 
and  the  vomiting  act  instituited  the  effects  are  1)  a  deep 
breath,  2)  raising  the  hyoid  bone  and  larynx  to  pull  the  upper 
oesophageal  sphincter  open  3)  closure  of  glottis  4)  lifiting  of 
soft  palate  to  close  the  posterior  nares,  5)  downward 
contraction  of  diaphragm  and  simultaneous  contraction  of 
abdominal  muscles,  compressing  the  stomach  in  between  and 
6)  finally  the  LES  relaxes  completely,  allowing  expulsion  of 
gastric contents through the mouth.
RISK FACTORS FOR PONV2-5
1) Patients related
Age :  incidence is low in infants, gradually increases towards 
adulthood and then decreases again in the elderly.
Sex :  Incidence in high in women, especially during ovulatory 
and luteal phase6 -7.
Anxiety  :    Causes  decreased  gastric  emptying.  Anxious 
infants  swallow  air  during  induction  and  vomit  due  to  gastric 
distention.  Pain  and  stress  release  catecholamines  which 
stimulate area postrema.
2) Anaesthesia related : 
Atropine : Decreased gastric emptying.
Opioids  : Directly  stimulate  CTZ  through  opioid  receptors. 
However,  if  opioids are not  given,  it  still  causes  vomiting due 
to increased pain.
Intravenous  anaesthetics:  Ketamine,  etomidate  based 
anaesthesia  have  been  proposed  to  cause  more  PONV  than 
thiopentone  and methohexitone.  Propofol  and midazolam have 
been shown to be associated with less PONV8 -1 1.
N2O: May cause increased PONV due to increase in middle ear 
pressure, bowel distention and sympathetic stimulation 1 2 ,  13 .
Volatiles  :  Due  to  sympathetic  stimulation  ether,  chloroform 
and  cyclopropane  are  more  frequently  associated  with  PONV 
than fluorinated anaesthetics. 
Neostigmine  : may  increase  PONV  due  to  increased  gut 
motility14 ,15 .
Neuraxial  blockade  :  Cephalad  migration  of  opioids  stimulate 
area  postrema1 6.  High  blockade,  due  to  unopposed  vagal  tone, 
increase  GI  peristalsis  and  cause  vomiting 17 .  Atropine  is 
effective in this situation18 ,19 .
PHARMACOLOGY OF ANTI – EMETIC DRUGS
Classification
1. Anticholinergics : Hyosine, Dicylomine
2. Antihistaminics (H1) : Promethazine, Diphenhydramine,
Dimenhydrinate, Cyclizine etc.,
3. Neuroleptics : Chlorpromazine, Haloperidol, droperidol.
4. Prokinetic : Metaclopromide, Domperidone, 
Lisapride, mosopride
5.5HT3 antagonists ondansetron, granisetron, dolansetron, etc.,
6. Adjuvants : Dexamethazone, Benzodiazepines, 
Cannanbinoids
7. Non -  Pharmacologic : Acupuncture 
Anticholinergics :
Hyoscine  (0.2  –  0.4mg  oral,  i.m)  and  dicyclomine  (10  – 
20mg  oral)  are  useful  for  the  prophylaxis  of  motion  sickness. 
They  probably  act  by  blocking  conduction  of  nerve  impulses 
across  a  cholinergic  link  in  the  pathway  leading  from 
vestibular  apparatus to the vomiting  centre.  However hyoscine 
produces  sedation  and  other  anticholinergic  side  effects.  A 
transdermal  patch  containing  1.5mg  of  hyoscine,  delivered 
over 3 days, produce only mild side effects2 0.
H1 Antihistaminics :
They  are  useful  mainly  in  prophylaxis  of  motion 
sickness.  They  are  also  used  in  the  prevention  of  post  op 
emesis2 1 ,  2 2.  The  effect  appear  to  be  based  on  anticholinergic, 
antihistaminic and sedative properties. By their anticholinergic 
action,  they  block  the  extrapyramidal  side  effect  of 
metaclopramide,  while  supplementing  its  antiemetic  action.  It 
is better to avoid them for morning sickness, as they have been 
suspected to have teratogenic potential.
                                                                          
Neuroleptics :
These  are  potent  anti-emetics,  act  by  blocking  D2 
receptors  in  CTZ  and  are  effective  in  PONV,  radiation  and 
chemotherapy  induced  vomiting,  and  morning  sickness.  They 
are  not  effective  in  motion  sickness,  the  vestibular  pathway 
does  not  involve  dopaminergic  link.  Main  side  effects  are 
sedation and acute muscle dystonia, especially in children.
Droperidol:
It  is  a  butyrophenone neuroleptic,  used  for  the  treatment 
and  prevention  of  PONV.  Larger  doses  of  droperidol 
(>20µg/kg)  results  in  dyskinesia,  restlessness  and  dysphoric 
reactions.  So  the  lowest  effective  dose  should  be  given  after 
induction of anesthesia for anti-emetic prophylaxis2 4 
Prokinetic drugs 
1) Metaclopramide :
It  is  chemically  related to procainamide  and acts  through 
both dopaminergic and serotonergic pathways.
a) D2 antagonism 
Metaclopramide  blocks  D2  receptors  and  increase  Ach 
release  in  GIT,  thereby  promoting  gastric  emptying  and  LES 
tone.  The  central  D2  blocking  action  on  CTZ  is  also 
responsible  for  its  anti-emetic  activity.  However,  it  has  no 
chlorpromazine  like  neuroleptic  action,  though  it  shares  the 
extra – pyramidal and hyperprolactineamic actions of CPZ.
b) 5 – HT4 agonism :
Activation  of  5  –  HT4  receptors  on  interneurones, 
promote  Ach  release  from primary  motor  neurons  innervating 
the  smooth  muscles.  This  promotes  gastric  hurrying  and 
improves LES tone.
c) 5- HT3 antagonism :
At  high  concentrations,  it  blocks  5  –  HT3  receptors 
present  on  inhibitory  myenteric  interneurones,  which  increase 
GI  emptying  through  release  of  non  –  adrenergic  non  – 
cholinergic (NANC) neurotransmitter.
Pharmacokinetics and Interactions 
 It  is  rapidly  absorbed  orally,  enters  brain,  crosses 
placenta  and  secreted  in  milk.  It  is  partly  conjucated  in  liver 
and excreted in urine within 24 hours. t½ is  3- 6 hours.
It  hastens  absorption  of  aspirin,  diazepam by facilitating 
gastric  emptying  and  reduces  absorption  of  digoxin, 
cimetidine.  By  blocking  DA  receptors  in  basal  ganglia,  it 
abolishes the therapeutic effect of levodopa.
Side effects :
Sedation,  dizziness,  diarrhoea,  muscle  dystonias  in 
children.  Long  term  use  causes  parkinsonism  and 
galactorrhoea.
Dose : 0.3 – 1.0 mg/kg im or iv
10 mg tds oral
The  combination  of  metaclopramide  10-20mg  iv  and 
droperidol  0.5-1mg  iv  appears  to  be  more  effective  than 
droperidol alone25 ,26 .
2) Domperidone :
 It is a D2 antagonist, chemically related to haloperidol.
Mechanism of action :
It  is  based  on  D2  receptor  blockade  in  upper  GI, 
promoting  gastric  emptying.  Unlike  metaclopramide,  its 
prokinetic actions are not blocked by atropine.
It  crosses  BBB  poorly,  extrapyramidal  side  effects  are 
rare.  It  does  not  abolish  the  therapeutic  effect  of  levodopa. 
However, it acts on CTZ, which is outside BBB.
Pharmacokinetics :
Well absorbed orally, but bioavailability is only 15% due 
to  first  pass  metabolism.  It  is  completely  biotransformed  and 
metabolites are excreted in urine. t½ is  7 - 8 hours 
Side effects :
Dry mouth,  loose  stools,  headache,  rashes,  galactorrhoea 
and rarely cardiac arrythmias on rapid iv injection.
Dose : 10 – 40mg (Children 0.3 – 0.6mg/kg) tds.
3) Cisapride and Mosapride
Both  are  mainly  prokinetic  drugs,  promoting  gastic 
emptying  and  LES  tone,  with  little  anti-emetic  property  as 
they have no action on D2 receptors.
Mechanism of action
Prokinetic  action  is  mainly  exerted  by  5  –  HT4  agonism 
and  5-  HT3  antagonism promoting  Ach  release  from myentric 
neurons.
Both lack D2 antagonism,  devoid of action on CTZ, does 
not produce extrapyramidal symptoms or hyperprolactinemia.
Pharmacokinetics:
Oral  bioavailability  is  38%.  Inactivated  by  CYP  3A4 
with  a  t  ½  of  10  hours.  Dose  should  be  reduced  in  liver 
disease.
Side effects:
Abdominal  cramps.  Diarrhea,  dizziness,  rise  in  serum 
transaminases.  At  high  concentrations,  cisapride  by  blocking 
delayed  rectifying  k+ channels  in  heart,  prolongs  Q-TC 
interval  and predisposes  to  Torsades  de  pointers  and VF.  This 
is not seen with mosapride.
Dose:
Cisapride: 10-20mg tds. Orally.
Mosapride: 5mg tds. Orally.
Adjuvant antiemetics
1). Corticosteroids:
Dexamethasone  8-20  mg  iv  can  reduce  nausea  and 
vomiting  due  to  chemotherapy  and  augment  the  efficacy  of 
other  primary  anti-emetics  like  metaclopramide  and 
ondensetron27 .
2). Benzodiazepines:
They  have  weak  anti-emetic  property,  based  mainly  on 
sedative  action2 8 ,2 9.  Used  as  adjuvant  to  other  anti-emetics, 
they  reduce  anxiety  and  produce  amnesia  for  the  unpleasant 
procedure.  They  also  suppress  dystonic  effects  of 
metaclopramide.
3). Cannabinoids:
Tetrahydrocannabinol  (9THC)  is  the  active  principle  of 
the  hallucinogen  cannabis  indica.  The  disorienting  and  other 
central  effects  limit  its  clinical  utility.  Dronabinol  is  less 
hallucinogenic and more anti-emetic than 9THC.
4). Neurokinin-1 antagonists:
They  are  effective  in  both  the  treatment  and  prevention 
of PONV. These compounds may act synergistically with 5HT 3 
antagonists.
Non-pharmacologic methods:
There  is  considerable  interest  in  acupuncture  for  its 
potential  to  prevent  PONV  with  minimal  side  effects  and 
expense.  However,  they  have  limited  effectiveness.  Available 
evidence  suggests  that  acupuncture  prevents  PONV  compared 
with placebo.
Most  studies  use  P6 (Nei-guan  or  pericardium)  point31 , 
located  between  palmaris  longus  and  flexor  carpi  radialis 
tendons,  4cm  proximal  to  distal  wrist  crease  and  1cm  below 
the skin. It is recommended that stimulation be initiated before 
induction.  Some  report  taping  a  small  needle  cap  over  the  P 6 
point as a means of acupressure stimulation 3 2 -3 4.
More  recently  Korean  hard  acupressure  was  shown to  be 
effective in PONV in adults and children.
PHARMACOLOGY OF 5HT3  ANTAGONISTS
Ondansetron:
It  is  a  carbazole  derivative,  introduced  in  the  early 
1990’s.  It  is  the  prototype  of  new  class  of  anti-emetic  drugs 
developed  to  control  chemotherapy  and  radiotherapy  induced 
vomiting and PONV.
Mechanism of action:
A.Cytotoxic  drugs  and  radiotherapy  produce  nausea  and 
vomiting  by  causing  cellular  damage  → release  of 
mediators  including  5HT  from  intestinal  mucosa  → 
activation  of  vagal  afferents  in  gut  → impulses  to  NTS 
and  CTZ.  Ondansetron  blocks  emetogenic  impulses  both 
at  their  peripheral  origin  and  central  relay.  It  does  not 
block dopamine receptors.
b. A weak gastrokinetic action due to 5HT3 blockole. 
c. A minor 5HT4 antagonistic action.
Pharmacokinetics: 
Oral  bioavailability  is  60-70%  due  to  first  pass 
mctabolism.  It  is  hydroxylated  by  CYP  1A2,  2D6  and  3A, 
eliminated  in  urine  and  faeces,  t1/2  3-5  hours,  duration  of 
action  4-12  hours.  No  significant  drug  interactions  have  been 
noted.
Dose and efficacy:
1. For  chemotherapy  induced  vomiting:  8mgiv  by  slow 
injection  over  15  minutes  ½  hour  before  chemotherapy, 
followed by 2 similar doses 4 hours apart.
2. For  PONV:  4-8mg  iv  (0.1-0.15mg/kg)  during  induction  and 
repeated if needed after 8-12 hours35 -42.
Patients  who  do  not  obtain  optimum  protection,  benefit 
from  addition  of  dexamethasone,  promethazine  or  diazepam. 
Adjuvants  are  more  often  required  for  delayed phase  vomiting 
that occurs on second to fourth day.
Availability :
4-8mg tablets
2mg/ml injection in 2ml, 4ml ampoules. 
Side effects:
Generally  well  tolerated.  Only  common  side  effect  is 
headache.  Mild  constipation,  diarrhea,  abdominal  discomfort, 
rashes and allergy (after iv injection) can occur.
Granisetron:
It is an indazole derivative, 10-15 times more potent than 
ondansetron.  The  mechanism  of  action  is  similar  to 
ondansetron,  except  that  the weak 5HT4  blockade has not  been 
detected in granisetron. t1/2 is 6-8 hours. Side effect  profile is 
similar  to  ondansetron.  It  is  useful  in  chemotherapy  induced 
vomiting and post op nausea and vomiting 4 3 -4 6.
Dose:  
20-40 µg/kg.
Availability:
1mg, 2mg tablets.
1mg/ml injection (1,3ml ampoules)
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MATERIALS AND METHODS 
This  is  a  randomized  double  blinded  study  conducted  at 
Madras  Medical  College.  A  total  of  60  patients  posted  for 
tonsillectomy  and  middle  ear  surgery  under  general  anesthesia 
were included. 
Inclusion criteria:  ASA I and II 
No history of motion sickness or prior 
PONV.      
     No history of any drug allergy.
After obtaining informed consent, patients were randomly 
assigned to one of the three treatment groups. 
a. Ondansetron 150µg/kg
b. Granisetron 40µg/kg 
c. Placebo (normal saline) 
by an anesthesiologist not involved in the 
assessment. A standardized anesthetic technique 
was followed 
after induction of 
anesthesia
Premedication: Inj. Glycopyrolate 0.05mg/kg.
 Inj. Pentazocine 0.5mg/kg.
i.m. 45 minutes before induction of anaesthesia.
After  pre-oxygenation  with  100%  O2  for  3  minutes, 
patients  were  induced  with  thiopentone  5mg/kg  and 
suxamethonium 2mg/kg  and  intubated  with  appropriated  sized 
endotracheal  tubes.  Patients  were  ventilated  with  IPPV  with 
N2O/O2 2:1  and  halothane  (if  needed,  to  maintain  stable 
heamodynamics),  paralysed  with  atracurium  0.5mg/kg 
initially,  then  0.1mg/kg.  At  the  end  of  surgery,  patients  were 
reversed  with  neostigmine  0.05mg/kg  and  glycopyrolate 
0.1mg/kg  and  extubated.  Intra-operatively  ECG,  HR,  spo 2 , 
NIBP  were  monitored.  Intra-op  and  post-op  fluids  comprised 
of Ringer lactate based on 4-2-1 rule.
Post-operatively  patients  were  assessed  for  nausea  and 
vomiting  in  the  early  post-op  period  (upto  1  hour),  upto  oral 
intake  and  upto  24  hours.  Presence  of  any  side  effects  and 
need  for  rescue  anti-emetic  (for  more  than  2  episodes  of 
vomiting)  were  noted.  Post-op  pain  was  treated  with 
acetaminophen suspension.
OBSERVATION AND RESULTS
Demographic Profile
All  parameters  were  comparable  between  the  three  groups  as 
evaluated by ANOVA test.
Age 
       F-test
Ondansetron 20 13.50 5.790 5 24
Granisetron 20 14.40 4.925 8 22
Placebo 20 12.00 4.702 7 22
F=1.1 
P=0.33
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Observation 
Nausea  and  vomiting  were  evaluated  in  three  periods  i.e. 
immediate post – op period (1 hr), upto oral intake and upto 24 hours 
using  chi  –  square  test.  The  presence  of  any  side  effects  were  also 
recorded.
 
 
group
Ondansetron Granisetron Placebo
n % n % n %
sex
 
male 11 55.0% 8 40.0% 13 65.0%
female 9 45.0% 12 60.0% 7 35.0%
surgery
 
Tonsil 14 70.0% 14 70.0% 14 70.0%
Middle ear 6 30.0% 6 30.0% 6 30.0%
Nausea
(period1)
 
no 15 75.0% 16 80.0% 8 40.0%
yes 5 25.0% 4 20.0% 12 60.0%
Nausea
(period2)
 
no 12 60.0% 14 70.0% 10 50.0%
yes 8 40.0% 6 30.0% 10 50.0%
Nausea
(period3)
 
no 17 85.0% 18 90.0% 8 40.0%
yes 3 15.0% 2 10.0% 12 60.0%
vomiting
(period1)
 
no 18 90.0% 20 100.0% 10 50.0%
yes 2 10.0% - - 10 50.0%
vomiting
(period2)
 
no 19 95.0% 18 90.0% 14 70.0%
yes 1 5.0% 2 10.0% 6 30.0%
vomiting
(period3)
 
no 19 95.0% 20 100.0% 13 65.0%
yes 1 5.0% - - 7 35.0%
Rescue
 
no 20 100.0% 20 100.0% 13 65.0%
yes - - - - 7 35.0%
headache
 
no 14 70.0% 15 75.0% 16 80.0%
yes 6 30.0% 5 25.0% 4 20.0%
Abdominal 
discomfort
 
no 17 85.0% 19 95.0% 20 100.0%
yes 3 15.0% 1 5.0%   
allergy no 20 100.0% 20 100.0% 20 100.0%
                     χ2 test          P-value
nauseia (Period 1)    8.4                0.02
nauseia (Period 2)  1.7                0.43
nauseia (Period 3) 14.9              0.001 
vomiting (Period 1)  17.5              0.001
vomiting (Period 2) 5.5                0.06
vomiting (Period 3)  12.4             0.002
rescue              15.8              0.001
headache           0.5                0.77
abdominal  discomfort        3.75              0.15
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It  is  observed  that  the  incidence  of  nausea  and  vomiting  was 
significantly less between ondansetron, and granisetron group compared 
with placebo group in all the periods except for the incidence of nausea 
(Period  2).  There  was  no  statistically  significant  difference  in  the 
incidence of side effect. 
Odds ratio
1.00
0.75
4.5
χ2 test   for trend = 5.2  P=0.02    
Odds ratio
1.00
0.63
3.78
χ2 test  for trend = 3.97  P=0.05     
     
Odds ratio
1.00
0.00
9.00
χ2 test  for trend = 9.8  P=0.001
Nausea(period1)
 no yes
 n % n %
  Ondansetron 15 38.5% 5 23.8%
 Granisetron 16 41.0% 4 19.0%
 Placebo 8 20.5% 12 57.1%
Nausea(period3)
no yes
 n % n %
Ondansetron 17 39.5% 3 17.6%
Granisetron 18 41.9% 2 11.8%
 Placebo 8 18.6% 12 70.6%
Vomiting (period1)
no yes
    n % n %
Ondansetron 18 37.5% 2 16.7%
Granisetron 20 41.7% - - 
 Placebo 10 20.8% 10 83.3%
Odds ratio
1.00
2.11
8.14
χ2 test  for trend = 4.8  P=0.05
Odds ratio
1.00
0.00
10.23
χ2 test  for trend = 7.6  P=0.005
From  the  above  values  the  odds  ratio  (Risk  ratio)  has  been 
calculated. The risk of getting nausea and vomiting is highest in placebo 
group and least is granisetron group.
rescue
no yes
 n % n %
Ondansetron 20 37.7% - - 
Granisetron 20 37.7% - - 
 Placebo 13 24.5% 7 100.0%
No patient in the ondansetron and granisetron group needed 
rescue antiemetics, where as nearly 65% in the placebo group required 
rescue drug. 
Vomiting (period2)
no yes
 n % n %
Ondansetron 19 37.3% 1 11.1%
Granisetron 18 35.3% 2 22.2%
 Placebo 14 27.5% 6 66.7%
Vomiting(period3)
no yes
 n % n %
Ondansetron 19 36.5% 1 12.5%
Granisetron 20 38.5% - - 
 Placebo 13 25.0% 7 87.5%
DISCUSSION
Nausea  and vomiting  are  both  unpleasant  and distressing 
to  the  patient,  surgeon  and  anaesthesiologist.  If  severe,  it  can 
lead  to  separation  of  suture  lines,  wound  dehiscence 
dehydration,  electrolyte  imbalance,  exhaustion  delayed 
discharge from hospital and increased cost to the patient.
Numerous  drugs  have  been  used  in  the  past  in  the 
prevention  of  post  –  operative  nausea  and  vomiting,  but  they 
also  have  been  associated  with  undesirable  side  effects.  For 
example,  metaclopramide  results  in  extrapyramidal  symptoms, 
droperidol  produces  restlessness  and  dysphoric  reactions, 
antihistaminics  result  in  sedation.  The  5  HT3  antagonists  are 
very  effective  in  preventing  post-operative  nausea  and 
vomiting  and do not  produce any significant  side  effects.  This 
study compares  the efficacy  of  ondansetron and granisetron in 
the prevention of post – operative nausea and vomiting.
Fuji Y et al have done two studies in patients undergoing 
tonsillectomy  and  middle  ear  surgery  comparing  granisetron 
and placebo. The incidence of PONV in their studies were 17% 
and  60%  in  tonsillectomies  and  17%  and  63%  in  middle  ear 
surgeries. In our study it was 30% and 85% respectively.
 
Morton  NS  et  al  compared  ondansetron  and  placebo  in 
patients  undergoing  tonsillectomy  and  demonstrated  the 
superiority   of  ondansetron.  The  incidence  of  nausea  was  36% 
and  49% and  the  incidence  of  vomiting  was  40% and  53%.  In 
our study it was 40% and 85% respectively. 
Dua  N  et  al  compared  granisetron  and  ondansetron  for 
the  prevention  of  nausea  and  vomiting  in  patients  undergoing 
modified  radical  mastectomy  and  demonstrated  that  the 
incidence  of  PONV  with  ondensetron  granisetron  and  placebo 
were 25%, 20% and 70% respectively. Our study findings
concurred  with  this  study  with  a  slightly  higher 
incidence, the figures being 40%, 30% and 85% respectively. 
No  clinically  significant  side  effects  were  noted  with 
both these drugs during our study.
  
SUMMARY
This  study  was  conducted  in  Madras  Medical  College  to 
compare  the  efficacy  of  ondansetron  and  granisetron  in  the 
prevention  of  post  –  operative  nausea  and  vomiting.  Sixty 
patients in the age group of 5 – 25 years and ASA I or II status 
were  chosen  and  randomly  allotted  to  be  in  each  of  the 
following treatment group.
a) Inj ondansetron
b) Inj Granisetron
c) Placebo 
After  obtaining  informed  consent,  the  patients  received 
the  drugs  after  induction  of  anaesthesia.  The  anaesthetic 
technique was standardized. The patients were assessed for the 
incidence of nausea and vomiting upto 24 hours.
We  found  that  both  ondansetron  and  granisetron  were 
effective  in  preventing nausea  and vomiting  with no clinically 
significant side effects.
CONCLUSION
We  compared  the  efficacy  of  ondansetron  and  granisetron  in 
patients undergoing tonsillectomy and middle ear surgery and found that 
both  drugs  were  effective  in  preventing  post  –  operative  nausea  and 
vomiting. There was a decrease in the requirements of rescue antiemetics, 
when these drugs were given. The side effects observed with these drugs 
were mild and clinically insignificant.
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PROFORMA
Name  : No:
Age / Sex : Diagnosis :
Weight : Procedure :
ASA Status : Investigations :
Group : A) Inj. Ondansetron 150 µg / kg
  B) Inj. Granisetron 40 µg/kg
   C) Placebo
Immediate Post – Op 
Period (upto 1 hour) 
Upto Oral 
intake
Upto 24 
hours
Incidence of Nausea 
Incidence of vomiting 
Duration of anaesthesia :
Oral fluids started at :
Rescue antiemetic : 
Side effects :
Head ache :
Abdominal discomfort :
Rash / Allergy :
 
After induction of 
anaesthesia
MASTER CHART
S.NO NAME
SEX 
/ 
AGE
SURGERY GROUP
NAUSEA 
Period
VOMITING
Period
1 2 3 1 2 3
RESCUE
ANTI 
-EMETIC
S
HEAD 
ACHE
ABDOMINAL.
DISCOMFORT
RASH/
ALLERGY
1. VIGNESWAR M/10 TONSIL ONDANSETRON - - - - - - - - - -
2. SUJATHA F/9 TONSIL ONDANSETRON - - - - - - - + - -
3. AMUTHA F/9 TONSIL ONDANSETRON + + + + - - - - + -
4. DIVYA F/5 TONSIL ONDANSETRON - - - - - - - - - -
5. PRAKASH M/7 TONSIL ONDANSETRON - - - - - - - + - -
6. MALATHY F/9 TONSIL ONDANSETRON + + - - - - - + - -
7. JOTHI F/12 TONSIL ONDANSETRON - - - - - - - - - -
8. LINGESWARAN M/9 TONSIL
ONDANSETRON - - - - - - - - - -
9. GOPI M/11 TONSIL ONDANSETRON + + + + - - - - - -
10. NASREEN F/12 TONSIL ONDANSETRON - - - - - - - - - -
11. SURESH M/14 TONSIL ONDANSETRON - - - - - - - + + -
12. FATHIMA F/20 TONSIL ONDANSETRON + + - - - - - - - -
13. SEKAR M/13 TONSIL ONDANSETRON - - - - - - - - - -
14. THARSEIVEL M/12 TONSIL ONDANSETRON + + - - + + - - - -
15. NAGARAJ M/24 ME ONDANSETRON - - - - - - - - + -
16. CHANDRAN M/22 ME ONDANSETRON - + + - - - - + - -
17. PARVATHY F/22 ME ONDANSETRON - - - - - - - - - -
18. DEEPAK M/11 ME ONDANSETRON - - - - - - - - - -
19. ANANDHI F/15 ME ONDANSETRON - + + - - - - - - -
20. RAMESH M/24 ME ONDANSETRON - - - - - - - + - -
MASTER CHART
S.NO NAME
SEX 
/ 
AGE
SURGERY GROUP
NAUSEA
Period
VOMITING
Period
1 2 3 1 2 3
RESCUE
ANTI-
EMETICS
HEAD 
ACHE
ABDOMINAL.
DISCOMFORT
RASH/
ALLERGY
21. GEETHA F/19 TONSIL GRANISETRON - - - - - - - - - -
22. MANIKANDAN M/12 TONSIL GRANISETRON - - - - - - - - - -
23. KOTHAI M/21 TONSIL GRANISETRON + + + - - - - + - -
24. RAJKUMAR M/12 TONSIL GRANISETRON - - - - - - - - - -
25. DAS M/22 TONSIL GRANISETRON - - - - - - - - - -
26. DINESH M/12 TONSIL GRANISETRON + + - - - - - + + -
27. SELVI F/12 TONSIL GRANISETRON - - - - - - - + - -
28. ANJALI F/11 TONSIL GRANISETRON - - - - - - - - - -
29. RUBINI F/10 TONSIL GRANISETRON - - - - - - - - - -
30. MANJULA F/9 TONSIL GRANISETRON + + + - + - - - - -
31. VANITHA F/9 TONSIL GRANISETRON - - - - - - - - - -
32. MOHARAPRIYA F/8 TONSIL GRANISETRON - - - - - - - + - -
33. GRACY F/12 TONSIL GRANISETRON - - - - - - - - - -
34. SUDHA F/9 TONSIL GRANISETRON + + - - - - - - - -
35. SHARTNA F/14 ME GRANISETRON - - - - - - - - - -
36. SAGAYAM F/22 ME GRANISETRON - - - - - - - - - -
37. BALAMMESAR M/22      ME GRANISETRON - + - - + - - - - -
38. SARAVANAN M/15 ME GRANISETRON - - - - - - - - - -
39. SURESH M/19      ME GRANISETRON - - - - - - - + - -
40. RAJI M/18 ME GRANISETRON - + - - - - - - - -
MASTER CHART
S.NO NAME
SEX 
/ 
AGE
SURGERY GROUP
NAUSEA
Period
VOMITING
Period
1 2 3 1 2 3
RESCUE
ANTI 
-EMETIC
S
HEAD 
ACHE
ABDOMINAL
DISCOMFORT
RASH/
ALLERGY
41. NARESH M/9 TONSIL PLACEBO - - + - - + - - - -
42. VIGNESH M/10 TONSIL PLACEBO + + + + - + + - - -
43. BHUVANESH M/10 TONSIL PLACEBO - - - - - - - - - -
44. JOSEPH M/7 TONSIL PLACEBO - - - - - - - + - -
45. ARUNKUMAR M/8 TONSIL PLACEBO + + - + + - - + - -
46. SAKTHI F/8 TONSIL PLACEBO - - + - - + - - - -
47. SAROJA F/10 TONSIL PLACEBO + + + + - + + - - -
48. PREMKUMAR M/8 TONSIL PLACEBO + + + + - + + - - -
49. SASIKALA F/10 TONSIL PLACEBO - + - - + - - - - -
50. POOVARNAM M/10 TONSIL PLACEBO + - + - - - - - - -
51. VIJAYBABU M/10 TONSIL PLACEBO + + + + + + + + - -
52. RISWAS F/12 TONSIL PLACEBO - - - - - - - - - -
53. DINESH M/12 TONSIL PLACEBO + - - - - - - - - -
54. REVATHY F/11 TONSIL PLACEBO + + + + + - + - - -
55. KANNAN M/10 ME PLACEBO - - + - - - - - - -
56. SENANRAJ M/10 ME PLACEBO + + + + + - + - - -
57. GOWRI F/18 ME PLACEBO - + - - + - - + - -
58. PERUMAL M/22 ME PLACEBO + - + + - - - - - -
59. MOHAN M/22 ME PLACEBO + - + + + + + - - -
60. CHITHRA F/21 ME PLACEBO + - - + - - - - - -
